Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Therapeutic antibodies targeting the angiotensin AT1R pathway in cancer
aTen Therapeutics is a Scottish pre-clinical biotechnology company developing therapeutic monoclonal antibodies against the angiotensin-II type I receptor (AT1R), which is overexpressed across a range of cancers. Its lead candidate, Tensinumab (ATN-E11), is a human monoclonal antibody generated via phage display that…
Epigenetic reprogramming and senolytic therapeutics for cancer and ageing
199 Biotechnologies is a preclinical-stage biotechnology company developing epigenetic reprogramming and senolytic therapies targeting cancer and age-related disease. Its lead programme applies partial cellular reprogramming to modify the behaviour of glioblastoma cells, reducing malignancy and reactivating natural…
Personalised T cell therapy platform for solid tumour treatment
Swarm Oncology is a pre-clinical biotechnology company developing personalised T cell therapies for advanced solid cancers. Its platform combines in vivo immune priming with proprietary ex vivo cell processing to generate large numbers of potent, non-exhausted T cells with tumour-homing phenotypes, addressing a key…
Molecular diagnostic assay development for oncology biomarkers
APIS Assay Technologies is a molecular diagnostics company developing and commercialising genomic assays for oncology and personalised medicine. The company combines an in-house biomarker research programme with contract assay development services, using PCR, digital PCR, and multi-omics platforms to translate…
Immunotherapies targeting blood cancer precursor conditions before onset
Athernal Bio is a Cambridge-based biotechnology company developing targeted immunotherapies for high-risk clonal haematopoiesis, a widespread blood stem cell mutation condition that significantly increases the risk of acute myeloid leukaemia and other haematological cancers. The company's pipeline comprises three…
Ultrasound-based platform to enhance drug delivery into solid tumours
OxSonics is a clinical-stage biotechnology company developing a proprietary drug delivery platform that uses focused ultrasound and injectable cavitation particles to enhance the penetration of anti-cancer agents into solid tumours. The system requires no drug reformulation and includes real-time acoustic mapping to…
Preclinical orexin-1 addiction therapies and CNS drug discovery
TheraCryf is an AIM-listed biotechnology company developing small-molecule therapies for addiction and other neuropsychiatric conditions. Its lead orexin-1 receptor antagonist programme is completing preclinical toxicology and regulatory preparations for a first-in-human Phase 1 trial in Australia. An Australian CRO…
Light-activated small molecule therapies for oral cancer and wound care
LightOx is a biotechnology company developing light-activated small molecule therapeutics for cancer and infection. Its lead candidate LXD191 is a topically applied photosensitising compound targeting early-stage oral cancer and pre-cancerous lesions, activated by a specific wavelength of light to generate reactive…
Cannabinoid medicines, neuroscience and oncology drug development
Jazz Pharmaceuticals is a global biopharmaceutical company focused on medicines for neuroscience and oncology. Its UK operations, centred at Kent Science Park in Sittingbourne, form the heart of its global cannabinoid manufacturing and research activities, inherited through its 2021 acquisition of GW Pharmaceuticals…
TCR therapeutic discovery platform targeting solid tumours
T-Cypher Bio is a pre-clinical biotechnology company developing T-cell receptor therapeutics using its proprietary platform, which integrates immunopeptidomics, bead-display microfluidics, and immune synapse mapping to identify novel intracellular targets and potent TCRs directly from patient tissue. The approach…
Pharmaceutical company in cardiometabolic, oncology, and immunology
Eli Lilly and Company is a multinational pharmaceutical company with UK operations headquartered in Basingstoke and an R&D site in Bracknell. Founded in 1876, Lilly's UK affiliate has operated since 1934 and employs approximately 700 people across regulatory, medical affairs, and research functions. The company…
Generative AI platform for T cell receptor and antibody therapeutics
Etcembly is a biotech company using generative AI to discover and engineer T cell receptor and antibody therapeutics. The company's platform applies large language models to TCR sequence data to design candidates with high affinity and selectivity for cancer and autoimmune disease targets. Its lead programme, ETC-101,…
Small molecule drugs targeting intrinsically disordered proteins in cancer
Kodiform Therapeutics is a drug discovery company developing first-in-class small molecule inhibitors against intrinsically disordered protein targets in cancer, a class historically considered undruggable due to the absence of stable binding pockets. The company uses intracellular antibody technology to identify and…
Specialist CRO for oncology, rare disease, and neurology clinical trials
Evestia Clinical is a global specialist contract research organisation providing full-service and functional clinical trial support to biotech and pharmaceutical companies. The company offers clinical operations, site and project management, regulatory affairs, biostatistics, pharmacovigilance, and medical writing…
Multiomics blood-based platform for early-stage cancer detection
Freenome is a biotechnology company developing blood-based early cancer detection tests using a multiomics platform that combines tumour and non-tumour biological signals with machine learning. The UK subsidiary, based in Nottingham, holds the autoantibody immunodiagnostic technology and cancer detection pipeline…
Novel ADC payloads targeting NMT enzymes in cancer
Myricx Bio is a clinical-stage biotechnology company developing a novel class of antibody-drug conjugate payloads based on inhibition of N-myristoyltransferase, an enzyme essential to cancer cell survival. Its NMTi payload chemistry platform addresses limitations of existing ADC payloads, including resistance and…
AI-enabled small molecule drug discovery
PharmEnable is a Cambridge-based drug discovery company developing novel small molecule therapeutics for targets that are inaccessible to biologics, including intracellular targets and those behind the blood-brain barrier. Its proprietary platform integrates AI and advanced medicinal chemistry to explore undercharted…
GMP lentiviral and retroviral vector design and manufacture for CGT
ViroCell Biologics is a specialist contract development and manufacturing organisation providing GMP design and manufacture of lentiviral and retroviral vectors for cell and gene therapy clinical trials. The company serves academic and corporate innovators developing CAR-T therapies, rare disease gene therapies, and…
AI decision support tools for blood cancer pathology diagnosis
Spotlight Pathology is a software company developing artificial intelligence decision support tools for haematopathology. Its platform applies computer vision models trained on clinical datasets to analyse digital images of lymph node and bone marrow biopsies, supporting pathologists in the diagnosis of blood cancers…
Defined live bacterial consortia for oncology and inflammatory bowel disease
Microbiotica is a clinical-stage biopharmaceutical company developing oral live biotherapeutic products comprising defined consortia of gut commensal bacterial strains. Candidate bacterial strains are identified by analysing microbiome data from clinical outcome studies, enabling mechanistically grounded strain…